| 27.8223 0.137 (0.49%) | 11-29 10:49 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.93 | 1-year : | 39.63 |
| Resists | First : | 29.04 | Second : | 33.93 |
| Pivot price | 27.26  |
|||
| Supports | First : | 27.06 | Second : | 25.83 |
| MAs | MA(5) : | 27.39 |
MA(20) : | 27.49 |
| MA(100) : | 28.46 |
MA(250) : | 27.5 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 55.2 |
D(3) : | 48.5 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 30.1 | Low : | 24.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CANC ] has closed below upper band by 34.5%. Bollinger Bands are 52.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.73 - 27.81 | 27.81 - 27.9 |
| Low: | 27.29 - 27.39 | 27.39 - 27.5 |
| Close: | 27.51 - 27.66 | 27.66 - 27.83 |
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Thu, 21 Nov 2024
Disruptive Theme of the Week: Breakthroughs in Medicine - ETF Trends
Sun, 17 Nov 2024
(CANC) Investment Analysis - Stock Traders Daily
Sun, 03 Nov 2024
7 Best-Performing Biotech ETFs for November 2024 - NerdWallet
Mon, 14 Oct 2024
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
Thu, 25 Apr 2024
How Big Pharma Is Taking A Page Out Of Novartis' Playbook - Investor's Business Daily
Wed, 06 Sep 2023
12 Best Healthcare ETFs To Buy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|